Skip to main content
Top
Published in: BMC Ophthalmology 1/2019

Open Access 01-12-2019 | Edema | Research article

Comparison of subfoveal choroidal thickness in eyes with CRVO and BRVO

Authors: Fen Tang, Fan Xu, Haibin Zhong, Xin Zhao, Mingliang Lv, Ke Yang, Chaolan Shen, Hui Huang, Jian Lv, Siming Zeng, Min Li, Qi Chen

Published in: BMC Ophthalmology | Issue 1/2019

Login to get access

Abstract

Background

To evaluate the subfoveal choroidal thickness (SFCT) in eyes with macular edema (ME) secondary to retinal vein occlusion(RVO), and to investigate the short term response after a single intravitreal ranibizumab (IVR) injection. What is more, to compare SFCT and SFCT change between central RVO (CRVO) and branch RVO (BRVO).

Methods

In the retrospective study, we had collected 36-six treatment-naïve patients with unilateral ME secondary to RVO (including 19 CRVO and 17 BRVO). All patients had received IVR injection after newly diagnosed. The SFCT was measured at the onset and after 2 weeks of IVR injection. Paired t test was performed to compare the SFCT of RVO eyes and fellow eyes, as well as the SFCT of pre-injection and post-injection. In further, independent t test was used to compare SFCT and SFCT change between CRVO eyes and BRVO eyes.

Results

The mean SFCT at the onset was 326.03 ± 30.86 μm in CRVO eyes, which was significantly thicker than that in contralateral fellow eyes (p < 0.01, paired t test), and reduced to 294.15 ± 30.83 μm rapidly after 2 weeks of IVR injection (p < 0.01, paired t test). Similarly, the SFCT in BRVO eyes was significantly thicker than that in contralateral eyes at the onset, and decreased significantly after IVR injection. However, our findings showed that there was no statistically significant difference in SFCT and SFCT reduction after IVR injection between CRVO eyes and BRVO eyes.

Conclusions

The SFCT in eyes with ME secondary to CRVO and BRVO was significantly thicker than that in fellow eyes, and decreased significantly within a short time in response to a single IVR injection. In further, the study showed that SFCT and SFCT change had no correlation with RVO subtypes.
Literature
1.
go back to reference Feltgen N, Pielen A. Retinal vein occlusion : epidemiology, classification and clinical findings. Ophthalmologe. 2015;112(7):607–18 quiz 19-20.CrossRef Feltgen N, Pielen A. Retinal vein occlusion : epidemiology, classification and clinical findings. Ophthalmologe. 2015;112(7):607–18 quiz 19-20.CrossRef
2.
go back to reference Ip M, Hendrick A. Retinal vein occlusion review. Asia Pac J Ophthalmol (Phila). 2018;7(1):40–5.CrossRef Ip M, Hendrick A. Retinal vein occlusion review. Asia Pac J Ophthalmol (Phila). 2018;7(1):40–5.CrossRef
3.
go back to reference Rogers S, McIntosh RL, Cheung N, Lim L, Wang JJ, Mitchell P, et al. The prevalence of retinal vein occlusion: pooled data from population studies from the United States, Europe, Asia, and Australia. Ophthalmology. 2010;117(2):313–9 e1.CrossRef Rogers S, McIntosh RL, Cheung N, Lim L, Wang JJ, Mitchell P, et al. The prevalence of retinal vein occlusion: pooled data from population studies from the United States, Europe, Asia, and Australia. Ophthalmology. 2010;117(2):313–9 e1.CrossRef
4.
go back to reference Pulido JS, Flaxel CJ, Adelman RA, Hyman L, Folk JC, Olsen TW. Retinal vein occlusions preferred practice pattern((R)) guidelines. Ophthalmology. 2016;123(1):P182–208.CrossRef Pulido JS, Flaxel CJ, Adelman RA, Hyman L, Folk JC, Olsen TW. Retinal vein occlusions preferred practice pattern((R)) guidelines. Ophthalmology. 2016;123(1):P182–208.CrossRef
5.
go back to reference Huang P, Niu W, Ni Z, Wang R, Sun X. A meta-analysis of anti-vascular endothelial growth factor remedy for macular edema secondary to central retinal vein occlusion. PLoS One. 2013;8(12):e82454.CrossRef Huang P, Niu W, Ni Z, Wang R, Sun X. A meta-analysis of anti-vascular endothelial growth factor remedy for macular edema secondary to central retinal vein occlusion. PLoS One. 2013;8(12):e82454.CrossRef
6.
go back to reference Noma H, Funatsu H, Mimura T, Harino S, Hori S. Vitreous levels of interleukin-6 and vascular endothelial growth factor in macular edema with central retinal vein occlusion. Ophthalmology. 2009;116(1):87–93.CrossRef Noma H, Funatsu H, Mimura T, Harino S, Hori S. Vitreous levels of interleukin-6 and vascular endothelial growth factor in macular edema with central retinal vein occlusion. Ophthalmology. 2009;116(1):87–93.CrossRef
7.
go back to reference Jumper JM, Dugel PU, Chen S, Blinder KJ, Walt JG. Anti-VEGF treatment of macular edema associated with retinal vein occlusion: patterns of use and effectiveness in clinical practice (ECHO study report 2). Clin Ophthalmol. 2018;12:621–9.CrossRef Jumper JM, Dugel PU, Chen S, Blinder KJ, Walt JG. Anti-VEGF treatment of macular edema associated with retinal vein occlusion: patterns of use and effectiveness in clinical practice (ECHO study report 2). Clin Ophthalmol. 2018;12:621–9.CrossRef
8.
go back to reference Freund KB, Korobelnik JF, Devenyi R, Framme C, Galic J, Herbert E, et al. Treat-And-Extend Regimens With Anti-Vegf Agents In Retinal Diseases: a literature review and consensus recommendations. Retina. 2015;35(8):1489–506.CrossRef Freund KB, Korobelnik JF, Devenyi R, Framme C, Galic J, Herbert E, et al. Treat-And-Extend Regimens With Anti-Vegf Agents In Retinal Diseases: a literature review and consensus recommendations. Retina. 2015;35(8):1489–506.CrossRef
9.
go back to reference Park J, Lee S, Son Y. Effects of two different doses of intravitreal bevacizumab on subfoveal choroidal thickness and retinal vessel diameter in branch retinal vein occlusion. Int J Ophthalmol. 2016;9(7):999–1005.PubMedPubMedCentral Park J, Lee S, Son Y. Effects of two different doses of intravitreal bevacizumab on subfoveal choroidal thickness and retinal vessel diameter in branch retinal vein occlusion. Int J Ophthalmol. 2016;9(7):999–1005.PubMedPubMedCentral
10.
go back to reference Qian T, Zhao M, Xu X. Comparison between anti-VEGF therapy and corticosteroid or laser therapy for macular oedema secondary to retinal vein occlusion: a meta-analysis. J Clin Pharm Ther. 2017;42(5):519–29.CrossRef Qian T, Zhao M, Xu X. Comparison between anti-VEGF therapy and corticosteroid or laser therapy for macular oedema secondary to retinal vein occlusion: a meta-analysis. J Clin Pharm Ther. 2017;42(5):519–29.CrossRef
11.
go back to reference Du KF, Xu L, Shao L, Chen CX, Zhou JQ, Wang YX, et al. Subfoveal choroidal thickness in retinal vein occlusion. Ophthalmology. 2013;120(12):2749–50.CrossRef Du KF, Xu L, Shao L, Chen CX, Zhou JQ, Wang YX, et al. Subfoveal choroidal thickness in retinal vein occlusion. Ophthalmology. 2013;120(12):2749–50.CrossRef
12.
go back to reference Tsuiki E, Suzuma K, Ueki R, Maekawa Y, Kitaoka T. Enhanced depth imaging optical coherence tomography of the choroid in central retinal vein occlusion. Am J Ophthalmol. 2013;156(3):543–7 e1.CrossRef Tsuiki E, Suzuma K, Ueki R, Maekawa Y, Kitaoka T. Enhanced depth imaging optical coherence tomography of the choroid in central retinal vein occlusion. Am J Ophthalmol. 2013;156(3):543–7 e1.CrossRef
13.
go back to reference Coban-Karatas M, Altan-Yaycioglu R, Ulas B, Sizmaz S, Canan H, Sariturk C. Choroidal thickness measurements with optical coherence tomography in branch retinal vein occlusion. Int J Ophthalmol. 2016;9(5):725–9.PubMedPubMedCentral Coban-Karatas M, Altan-Yaycioglu R, Ulas B, Sizmaz S, Canan H, Sariturk C. Choroidal thickness measurements with optical coherence tomography in branch retinal vein occlusion. Int J Ophthalmol. 2016;9(5):725–9.PubMedPubMedCentral
14.
go back to reference Lee EK, Han JM, Hyon JY, Yu HG. Changes in choroidal thickness after intravitreal dexamethasone implant injection in retinal vein occlusion. Br J Ophthalmol. 2015;99(11):1543–9.CrossRef Lee EK, Han JM, Hyon JY, Yu HG. Changes in choroidal thickness after intravitreal dexamethasone implant injection in retinal vein occlusion. Br J Ophthalmol. 2015;99(11):1543–9.CrossRef
15.
go back to reference Arifoglu HB, Duru N, Altunel O, Baskan B, Alabay B, Atas M. Short-term effects of intravitreal dexamethasone implant (OZURDEX(R)) on choroidal thickness in patients with naive branch retinal vein occlusion. Arq Bras Oftalmol. 2016;79(4):243–6.CrossRef Arifoglu HB, Duru N, Altunel O, Baskan B, Alabay B, Atas M. Short-term effects of intravitreal dexamethasone implant (OZURDEX(R)) on choroidal thickness in patients with naive branch retinal vein occlusion. Arq Bras Oftalmol. 2016;79(4):243–6.CrossRef
16.
go back to reference Yumusak E, Ornek K, Dikel NH. Comparison of choroidal thickness changes following intravitreal dexamethasone, ranibizumab, and triamcinolone in eyes with retinal vein occlusion. Eur J Ophthalmol. 2016;26(6):627–32.CrossRef Yumusak E, Ornek K, Dikel NH. Comparison of choroidal thickness changes following intravitreal dexamethasone, ranibizumab, and triamcinolone in eyes with retinal vein occlusion. Eur J Ophthalmol. 2016;26(6):627–32.CrossRef
17.
go back to reference Noma H, Funatsu H, Yamasaki M, Tsukamoto H, Mimura T, Sone T, et al. Pathogenesis of macular edema with branch retinal vein occlusion and intraocular levels of vascular endothelial growth factor and interleukin-6. Am J Ophthalmol. 2005;140(2):256–61.CrossRef Noma H, Funatsu H, Yamasaki M, Tsukamoto H, Mimura T, Sone T, et al. Pathogenesis of macular edema with branch retinal vein occlusion and intraocular levels of vascular endothelial growth factor and interleukin-6. Am J Ophthalmol. 2005;140(2):256–61.CrossRef
18.
go back to reference Miller JW, Le Couter J, Strauss EC, Ferrara N. Vascular endothelial growth factor a in intraocular vascular disease. Ophthalmology. 2013;120(1):106–14.CrossRef Miller JW, Le Couter J, Strauss EC, Ferrara N. Vascular endothelial growth factor a in intraocular vascular disease. Ophthalmology. 2013;120(1):106–14.CrossRef
19.
go back to reference Iijima H. Mechanisms of vision loss in eyes with macular edema associated with retinal vein occlusion. Jpn J Ophthalmol. 2018;62(3):265–73.CrossRef Iijima H. Mechanisms of vision loss in eyes with macular edema associated with retinal vein occlusion. Jpn J Ophthalmol. 2018;62(3):265–73.CrossRef
20.
go back to reference Franco-Cardenas V, Shah SU, Apap D, Joseph A, Heilweil G, Zutis K, et al. Assessment of ischemic index in retinal vascular diseases using ultra-wide-field fluorescein angiography: single versus summarized image. Semin Ophthalmol. 2017;32(3):353–7.CrossRef Franco-Cardenas V, Shah SU, Apap D, Joseph A, Heilweil G, Zutis K, et al. Assessment of ischemic index in retinal vascular diseases using ultra-wide-field fluorescein angiography: single versus summarized image. Semin Ophthalmol. 2017;32(3):353–7.CrossRef
21.
go back to reference Yasuda S, Kachi S, Ueno S, Ushida H, Piao CH, Kondo M, et al. Electroretinograms and level of aqueous vascular endothelial growth factor in eyes with hemicentral retinal vein occlusion or branch retinal vein occlusion. Jpn J Ophthalmol. 2014;58(3):232–6.CrossRef Yasuda S, Kachi S, Ueno S, Ushida H, Piao CH, Kondo M, et al. Electroretinograms and level of aqueous vascular endothelial growth factor in eyes with hemicentral retinal vein occlusion or branch retinal vein occlusion. Jpn J Ophthalmol. 2014;58(3):232–6.CrossRef
22.
go back to reference Flores-Moreno I, Lugo F, Duker JS, Ruiz-Moreno JM. The relationship between axial length and choroidal thickness in eyes with high myopia. Am J Ophthalmol. 2013;155(2):314–9 e1.CrossRef Flores-Moreno I, Lugo F, Duker JS, Ruiz-Moreno JM. The relationship between axial length and choroidal thickness in eyes with high myopia. Am J Ophthalmol. 2013;155(2):314–9 e1.CrossRef
23.
go back to reference Woodman EC, Read SA, Collins MJ. Axial length and choroidal thickness changes accompanying prolonged accommodation in myopes and emmetropes. Vis Res. 2012;72:34–41.CrossRef Woodman EC, Read SA, Collins MJ. Axial length and choroidal thickness changes accompanying prolonged accommodation in myopes and emmetropes. Vis Res. 2012;72:34–41.CrossRef
24.
go back to reference Ruiz-Medrano J, Flores-Moreno I, Pena-Garcia P, Montero JA, Duker JS, Ruiz-Moreno JM. Macular choroidal thickness profile in a healthy population measured by swept-source optical coherence tomography. Invest Ophthalmol Vis Sci. 2014;55(6):3532–42.CrossRef Ruiz-Medrano J, Flores-Moreno I, Pena-Garcia P, Montero JA, Duker JS, Ruiz-Moreno JM. Macular choroidal thickness profile in a healthy population measured by swept-source optical coherence tomography. Invest Ophthalmol Vis Sci. 2014;55(6):3532–42.CrossRef
25.
go back to reference Fujiwara A, Shiragami C, Shirakata Y, Manabe S, Izumibata S, Shiraga F. Enhanced depth imaging spectral-domain optical coherence tomography of subfoveal choroidal thickness in normal Japanese eyes. Jpn J Ophthalmol. 2012;56(3):230–5.CrossRef Fujiwara A, Shiragami C, Shirakata Y, Manabe S, Izumibata S, Shiraga F. Enhanced depth imaging spectral-domain optical coherence tomography of subfoveal choroidal thickness in normal Japanese eyes. Jpn J Ophthalmol. 2012;56(3):230–5.CrossRef
26.
go back to reference Abdolrahimzadeh S, Parisi F, Scavella V, Recupero SM. Optical coherence tomography evidence on the correlation of choroidal thickness and age with vascularized retinal layers in Normal eyes. Retina. 2016;36(12):2329–38.CrossRef Abdolrahimzadeh S, Parisi F, Scavella V, Recupero SM. Optical coherence tomography evidence on the correlation of choroidal thickness and age with vascularized retinal layers in Normal eyes. Retina. 2016;36(12):2329–38.CrossRef
27.
go back to reference Gaudreault J, Fei D, Beyer JC, Ryan A, Rangell L, Shiu V, et al. Pharmacokinetics and retinal distribution of ranibizumab, a humanized antibody fragment directed against VEGF-A, following intravitreal administration in rabbits. Retina. 2007;27(9):1260–6.CrossRef Gaudreault J, Fei D, Beyer JC, Ryan A, Rangell L, Shiu V, et al. Pharmacokinetics and retinal distribution of ranibizumab, a humanized antibody fragment directed against VEGF-A, following intravitreal administration in rabbits. Retina. 2007;27(9):1260–6.CrossRef
28.
go back to reference Rayess N, Rahimy E, Ying GS, Pefkianaki M, Franklin J, Regillo CD, et al. Baseline choroidal thickness as a short-term predictor of visual acuity improvement following antivascular endothelial growth factor therapy in branch retinal vein occlusion. Br J Ophthalmol. 2019;103(1):55–59.CrossRef Rayess N, Rahimy E, Ying GS, Pefkianaki M, Franklin J, Regillo CD, et al. Baseline choroidal thickness as a short-term predictor of visual acuity improvement following antivascular endothelial growth factor therapy in branch retinal vein occlusion. Br J Ophthalmol. 2019;103(1):55–59.CrossRef
29.
go back to reference Rayess N, Rahimy E, Ying GS, Bagheri N, Ho AC, Regillo CD, et al. Baseline choroidal thickness as a predictor for response to anti-vascular endothelial growth factor therapy in diabetic macular edema. Am J Ophthalmol. 2015;159(1):85–91 e1-3.CrossRef Rayess N, Rahimy E, Ying GS, Bagheri N, Ho AC, Regillo CD, et al. Baseline choroidal thickness as a predictor for response to anti-vascular endothelial growth factor therapy in diabetic macular edema. Am J Ophthalmol. 2015;159(1):85–91 e1-3.CrossRef
30.
go back to reference Karkhaneh R, Nikbakht M, Bazvand F, Oskouei AK, Ghasemi H, Ghassemi F. Choroidal thickness in idiopathic macular hole. J Curr Ophthalmol. 2017;29(1):45–9.CrossRef Karkhaneh R, Nikbakht M, Bazvand F, Oskouei AK, Ghasemi H, Ghassemi F. Choroidal thickness in idiopathic macular hole. J Curr Ophthalmol. 2017;29(1):45–9.CrossRef
31.
go back to reference Lu L, Xu S, He F, Liu Y, Zhang Y, Wang J, et al. Assessment of choroidal microstructure and subfoveal thickness change in eyes with different stages of age-related macular degeneration. Medicine (Baltimore). 2016;95(10):e2967.CrossRef Lu L, Xu S, He F, Liu Y, Zhang Y, Wang J, et al. Assessment of choroidal microstructure and subfoveal thickness change in eyes with different stages of age-related macular degeneration. Medicine (Baltimore). 2016;95(10):e2967.CrossRef
32.
go back to reference Chung YR, Kim JW, Kim SW, Lee K. Choroidal thickness in patients with central serous chorioretinopathy: assessment of Haller and Sattler layers. Retina. 2016;36(9):1652–7.CrossRef Chung YR, Kim JW, Kim SW, Lee K. Choroidal thickness in patients with central serous chorioretinopathy: assessment of Haller and Sattler layers. Retina. 2016;36(9):1652–7.CrossRef
33.
go back to reference Maruko I, Iida T, Sugano Y, Go S, Sekiryu T. Subfoveal choroidal thickness in papillitis type of vogt-koyanagi-harada disease and idiopathic optic neuritis. Retina. 2016;36(5):992–9.CrossRef Maruko I, Iida T, Sugano Y, Go S, Sekiryu T. Subfoveal choroidal thickness in papillitis type of vogt-koyanagi-harada disease and idiopathic optic neuritis. Retina. 2016;36(5):992–9.CrossRef
34.
go back to reference Eliwa TF, Hegazy OS, Mahmoud SS, Almaamon T. Choroidal thickness change in patients with diabetic macular edema. Ophthalmic Surg Lasers Imaging Retina. 2017;48(12):970–7.CrossRef Eliwa TF, Hegazy OS, Mahmoud SS, Almaamon T. Choroidal thickness change in patients with diabetic macular edema. Ophthalmic Surg Lasers Imaging Retina. 2017;48(12):970–7.CrossRef
35.
go back to reference Abadia B, Sunen I, Calvo P, Bartol F, Verdes G, Ferreras A. Choroidal thickness measured using swept-source optical coherence tomography is reduced in patients with type 2 diabetes. PLoS One. 2018;13(2):e0191977.CrossRef Abadia B, Sunen I, Calvo P, Bartol F, Verdes G, Ferreras A. Choroidal thickness measured using swept-source optical coherence tomography is reduced in patients with type 2 diabetes. PLoS One. 2018;13(2):e0191977.CrossRef
36.
go back to reference Rewbury R, Want A, Varughese R, Chong V. Subfoveal choroidal thickness in patients with diabetic retinopathy and diabetic macular oedema. Eye (Lond). 2016;30(12):1568–72.CrossRef Rewbury R, Want A, Varughese R, Chong V. Subfoveal choroidal thickness in patients with diabetic retinopathy and diabetic macular oedema. Eye (Lond). 2016;30(12):1568–72.CrossRef
37.
go back to reference Kim KH, Lee DH, Lee JJ, Park SW, Byon IS, Lee JE. Regional choroidal thickness changes in branch retinal vein occlusion with macular edema. Ophthalmologica. 2015;234(2):109–18.CrossRef Kim KH, Lee DH, Lee JJ, Park SW, Byon IS, Lee JE. Regional choroidal thickness changes in branch retinal vein occlusion with macular edema. Ophthalmologica. 2015;234(2):109–18.CrossRef
38.
go back to reference Rayess N, Rahimy E, Ying GS, Pefkianaki M, Franklin J, Regillo CD, et al. Baseline choroidal thickness as a short-term predictor of visual acuity improvement following antivascular endothelial growth factor therapy in branch retinal vein occlusion. Br J Ophthalmol. 2019;103(1):55–9.CrossRef Rayess N, Rahimy E, Ying GS, Pefkianaki M, Franklin J, Regillo CD, et al. Baseline choroidal thickness as a short-term predictor of visual acuity improvement following antivascular endothelial growth factor therapy in branch retinal vein occlusion. Br J Ophthalmol. 2019;103(1):55–9.CrossRef
39.
go back to reference Hasegawa T, Kawano T, Maruko I, Koizumi H, Iida T. Clinical findings of eyes with macular edema associated with branch retinal vein occlusion refractory to Ranibizumab. Retina. 2018;38(7):1347–53.CrossRef Hasegawa T, Kawano T, Maruko I, Koizumi H, Iida T. Clinical findings of eyes with macular edema associated with branch retinal vein occlusion refractory to Ranibizumab. Retina. 2018;38(7):1347–53.CrossRef
40.
go back to reference Quinlan PM, Elman MJ, Bhatt AK, Mardesich P, Enger C. The natural course of central retinal vein occlusion. Am J Ophthalmol. 1990;110(2):118–23.CrossRef Quinlan PM, Elman MJ, Bhatt AK, Mardesich P, Enger C. The natural course of central retinal vein occlusion. Am J Ophthalmol. 1990;110(2):118–23.CrossRef
41.
go back to reference Minturn J, Brown GC. Progression of nonischemic central retinal vein obstruction to the ischemic variant. Ophthalmology. 1986;93(9):1158–62.CrossRef Minturn J, Brown GC. Progression of nonischemic central retinal vein obstruction to the ischemic variant. Ophthalmology. 1986;93(9):1158–62.CrossRef
42.
go back to reference Maruko I, Iida T, Sugano Y, Ojima A, Sekiryu T. Subfoveal choroidal thickness in fellow eyes of patients with central serous chorioretinopathy. Retina. 2011;31(8):1603–8.CrossRef Maruko I, Iida T, Sugano Y, Ojima A, Sekiryu T. Subfoveal choroidal thickness in fellow eyes of patients with central serous chorioretinopathy. Retina. 2011;31(8):1603–8.CrossRef
43.
go back to reference Maruko I, Iida T, Sugano Y, Furuta M, Sekiryu T. One-year choroidal thickness results after photodynamic therapy for central serous chorioretinopathy. Retina. 2011;31(9):1921–7.CrossRef Maruko I, Iida T, Sugano Y, Furuta M, Sekiryu T. One-year choroidal thickness results after photodynamic therapy for central serous chorioretinopathy. Retina. 2011;31(9):1921–7.CrossRef
Metadata
Title
Comparison of subfoveal choroidal thickness in eyes with CRVO and BRVO
Authors
Fen Tang
Fan Xu
Haibin Zhong
Xin Zhao
Mingliang Lv
Ke Yang
Chaolan Shen
Hui Huang
Jian Lv
Siming Zeng
Min Li
Qi Chen
Publication date
01-12-2019
Publisher
BioMed Central
Keywords
Edema
Ranibizumab
Published in
BMC Ophthalmology / Issue 1/2019
Electronic ISSN: 1471-2415
DOI
https://doi.org/10.1186/s12886-019-1143-9

Other articles of this Issue 1/2019

BMC Ophthalmology 1/2019 Go to the issue